Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,375.0	$ 1,049.9
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively	1,404.8	1,664.1
Due from anti-CD20 therapeutic programs	464.0	435.9
Inventory	2,460.5	2,527.4
Other current assets	752.5	1,182.0
Total current assets	7,456.8	6,859.3
Property, plant and equipment, net	3,181.3	3,309.7
Operating lease assets	356.4	420.0
Intangible assets, net	9,691.2	8,363.0
Goodwill	6,478.9	6,219.2
Deferred tax asset	324.2	928.6
Investments and other assets	560.5	745.0
Total assets	28,049.3	26,844.8
Current liabilities:
Current portion of notes payable and term loan	1,748.6	150.0
Taxes payable	548.3	257.4
Accounts payable	424.2	403.3
Accrued expense and other	2,807.7	2,623.6
Total current liabilities	5,528.8	3,434.3
Notes payable and term loan	4,547.2	6,788.2
Deferred tax liability	190.5	641.8
Long-term operating lease liabilities	334.5	400.0
Other long-term liabilities	732.3	781.1
Total liabilities	11,333.3	12,045.4
Commitments, contingencies and guarantees (Notes 22 and 23)
Biogen Inc. shareholders’ equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	569.4	302.5
Accumulated other comprehensive income (loss)	(136.2)	(153.7)
Retained earnings	19,259.8	17,627.6
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively	(2,977.1)	(2,977.1)
Total equity	16,716.0	14,799.4
Total liabilities and equity	$ 28,049.3	$ 26,844.8